Received Sep 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | D4774 | — |
Early Third Dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 37-year-old female patient who received HAB (Twinrix) (batch number D4774, expiry date 12-SEP-2026) for prophylaxis. Concomitant products included Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix) and Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix). On 10-MAY-2025, the patient received the 3rd dose of Twinrix. On 10-MAY-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: Early Third Dose). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-SEP-2025 The reporter reported that patient wanted to come in for her third shot and noted that the schedule was zero, one, six months but she has gotten one in March and then another in April and one month later again in May as had early third dose which led to shortening of vaccine schedule. The vaccines were given as follows 1st dose was given on 9th March 2025, 2nd dose on 9th April 2025 and 3rd dose on 10th May 2025.
TWINRIX; TWINRIX